SCHEMBL4240719

SCHEMBL4240719

NC(=O)C(C(=O)Nc1ncc[nH]1)c1ccccc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR2 O15552 1/20 0.51
▸ ADRA2A P08913 2/20 0.44
▸ ADRA2C P18825 2/20 0.44
▸ ADRA1D P25100 2/20 0.44
▸ ADRA1A P35348 2/20 0.44
▸ ADRA1B P35368 2/20 0.44
▸ PTGES O14684 7/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ NR3C1 P04150 1/20 0.37
▸ CYP2C19 P33261 1/20 0.35
▸ CSNK1A1 P48729 1/20 0.35
▸ TYRO3 Q06418 1/20 0.35
▸ DYRK1B Q9Y463 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CXCL8 P10145 1/20 0.35
▸ ROCK2 O75116 1/20 0.35
▸ FDPS P14324 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4243726 0.85 FFAR2 (0.45) FFAR2PTGESNR3C1CSNK1A1TYRO3
SCHEMBL4247079 0.81 FFAR2 (0.49) FFAR2ADRA2AADRA2CADRA1DADRA1A
SCHEMBL4239786 0.79 FFAR2 (0.67) FFAR2ADRA2AADRA2CADRA1DADRA1A
SCHEMBL4239132 0.78 FFAR2 (0.52) FFAR2ADRA2AADRA2CADRA1DADRA1A
SCHEMBL4240812 0.75 FFAR2 (0.44) FFAR2PTGESROCK2
SCHEMBL4242107 0.74 FFAR2 (0.53) FFAR2PTGESNR3C1SMN1; SMN2FDPS
SCHEMBL4242694 0.74 FFAR2 (0.50) FFAR2PTGESNR3C1CSNK1A1TYRO3
SCHEMBL9518776 0.72 CXCL8 (0.47) KMT2ACXCL8CYP1A2
SCHEMBL4240372 0.71 FFAR2 (0.44) FFAR2PTGESNR3C1FDPS
SCHEMBL4244243 0.71 FFAR2 (0.50) FFAR2ADRA2AADRA2CADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 — — US claimed
US-8946259-B2 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2015-02-03 — — US disclosed
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2014-03-06 — — US disclosed
US-8598353-B2 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2013-12-03 — — US disclosed
EP-2457901-A1 Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors High Point Pharmaceuticals, LLC (US) 2012-05-30 — — EP disclosed
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors VTVX HOLDINGS II LLC 2009-12-31 — — US disclosed
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP FFAR2 4632/4885ADRA2A 2546/4885ADRA2C 1588/4885
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors BACE1, BACE2, APP FFAR2 4632/4885ADRA2A 2546/4885ADRA2C 1588/4885
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP FFAR2 4632/4885ADRA2A 2546/4885ADRA2C 1588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback